Santen Pharmaceutical Co., Ltd. provided consolidated earnings forecasts for the fiscal year ending March 31, 2024. For the year, on a core basis, the company expects revenue of ¥273,000 million, core operating profit of ¥46,000 million, core net profit for the year of ¥34,500 million and basic core earnings per share of ¥94.27. On IFRS basis, the company expects revenue of ¥273,000 million, operating profit of ¥32,000 million, net profit for the year of ¥22,400 million and basic earnings per share of ¥61.24.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,529 JPY | +0.39% | +2.51% | +8.83% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.83% | 3.62B | |
+26.08% | 681B | |
+21.85% | 556B | |
-4.77% | 361B | |
+16.97% | 325B | |
+5.69% | 285B | |
+13.68% | 235B | |
+3.65% | 199B | |
-11.12% | 189B | |
-3.40% | 157B |
- Stock Market
- Equities
- 4536 Stock
- News Santen Pharmaceutical Co., Ltd.
- Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024